AI Article Synopsis
- Atrial fibrillation is the most common persistent irregular heartbeat, and this study focuses on identifying patients at high risk for stroke or transient ischemic attacks (TIA) based on their mean platelet volume (MPV).
- Among 90 patients with paroxysmal atrial fibrillation, those with a history of stroke/TIA had significantly higher MPV levels compared to asymptomatic patients (11.1 fL vs. 9.1 fL).
- The research suggests that measuring MPV, alongside traditional risk scores like CHA2DS2VASc, could help identify atrial fibrillation patients at increased risk for stroke or TIA.
Article Abstract
Atrial fibrillation is the most common sustained arrhythmia in clinical practice. It is important to specify patients with a high risk of thromboembolus due to elevated procoagulant and prothrombotic state. The aim of this study is to assess the relation of stroke/transient ischaemic attack (TIA) with mean platelet volume (MPV), which is an indicator of platelet activation in patients with paroxysmal atrial fibrillation (PAF). Patients with PAF were enrolled in this study during years of 2012-2014. Patients were divided into two groups according to the presence or absence of stroke/TIA. Demographic data were registered and CHA2DS2VASc scores of patients were calculated. It was investigated whether there was a difference among groups regarding MPV levels. Ninety patients, 31 of whom had history of stroke/TIA (symptomatic group), were enrolled to study. CHA2DS2VASc score of symptomatic group was 4.77 ± 1.26, while CHA2DS2VASc score of asymptomatic group was 2.63 ± 1.41. Nevertheless, there was not any difference regarding CHA2DS2VASc score among two groups when 2 points due to stroke/TIA were subtracted in symptomatic patients. MPV was detected higher in symptomatic patients than asymptomatic patients (11.1 ± 1.3 vs. 9.1 ± 1.0 fL, P < 0.001, respectively). A value of 9.85 for the MPV ascertained with receiver operating characteristic (ROC) curve analysis to predict stroke/TIA was found to have a sensitivity of 87% and specificity of 78%. Elevated MPV levels were ascertained to be related with stroke/TIA in patients with PAF. Assessment of MPV apart from CHA2DS2VASc score in patients with PAF might be subsidiary to specify patients with an enhanced risk of stroke/TIA.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/MBC.0000000000000334 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Impact of Social Determinants of Health on Primary Adherence of Oral Anticoagulants Among Patients with Newly Diagnosed Atrial Fibrillation.
Cardiol Ther
January 2025
Advocate Aurora Research Institute, Advocate Health, 945 N 12th St, Milwaukee, WI, 53233, USA.
Introduction: Oral anticoagulants (OAC) reduce the risk of stroke among patients with atrial fibrillation (AF). However, adherence remains suboptimal. We focused on primary nonadherence to OAC and its associations with patient characteristics-specifically social determinants of health collected in electronic health records (EHR).
View Article and Find Full Text PDFClinical Manifestations.
Alzheimers Dement
December 2024
University of Naples Federico II, Napoli, Italy.
Background: Drugs with anticholinergic properties are frequently prescribed to patients with cognitive impairment. The cholinergic system plays an important role in the learning process, memory, but also in the regulation of emotions. The aim of this research is to investigate a possible correlation between the use of anticholinergic drugs and the risk of developing more severe behavioral and psychological symptoms (BPSD).
View Article and Find Full Text PDFAtrial fibrillation ablation timing: where is the sweet spot?
Eur Heart J
January 2025
Centre for Heart Rhythm Disorders, University of Adelaide and Royal Adelaide Hospital, Port Rd., Adelaide 5000, Australia.
Convincing evidence for the efficacy of ablation as first-line therapy in paroxysmal AF (PAF) and its clear superiority to medical therapy for rhythm control in both PAF and persistent AF (PsAF) has generated considerable interest in the optimal timing of ablation. Based on this data, there is a widespread view that the principle of 'the earlier the better' should be generally applied. However, the natural history of AF is highly variable and non-linear, and for this reason, it is difficult to be emphatic that all patients are best served by ablation early after their initial AF episodes.
View Article and Find Full Text PDFAtrial fibrillation status and associations with adverse clinical outcomes in patients hospitalised with COVID-19: a large unselected statewide population-linkage study.
Eur Heart J Qual Care Clin Outcomes
January 2025
Concord Repatriation General Hospital, Department of Cardiology, Concord, NSW, Australia.
Background: Atrial fibrillation (AF) is common in COVID-19 patients. The impact of AF on major-adverse-cardiovascular-events (MACE defined as all-cause mortality, myocardial infarction, ischemic stroke, cardiac failure or coronary revascularisation), recurrent AF admission and venous thromboembolism in hospitalised COVID-19 patients is unclear.
Methods: Patients admitted with COVID-19 (1-January-2020 to 30-September-2021) were identified from the New South Wales Admitted-Patient-Data-Collection database, stratified by AF status (no-AF vs prior-AF or new-AF during index COVID-19 admission) and followed-up until 31-Mar-2022.
Population Pharmacokinetics and Pharmacodynamics of Sotalol Following Expedited Intravenous Loading in Patients With Atrial Arrhythmias.
CPT Pharmacometrics Syst Pharmacol
January 2025
Division of Clinical Pharmacology, Department of Pediatrics, Spencer Fox Eccles School of Medicine, University of Utah, Salt Lake City, Utah, USA.
Sotalol, a class III antiarrhythmic agent, is used to maintain sinus rhythm in patients with atrial fibrillation or atrial flutter (AFIB/AFL). Despite its efficacy, sotalol's use is limited by its potential to cause life-threatening ventricular arrhythmias due to QT interval prolongation. Traditionally, sotalol administration required hospitalization to monitor these risks.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!